BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including GBM, demonstrated disease control in 48% of evaluable patients at therapeutic dose levels, with notable responses in DDR-deficient cancers such as NSCLC, colon cancer, thymic carcinoma, and GIST. No dose-limiting toxicities were observed, and adverse events were predominantly mild. Lantern plans to advance LP-184 into Phase 1b…
